18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01713049|
Recruitment Status : Unknown
Verified August 2010 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : October 24, 2012
Last Update Posted : October 24, 2012
|Condition or disease||Intervention/treatment||Phase|
|Breast Neoplasms||Drug: 18F-FLT||Not Applicable|
- To investigate the diagnostic accuracy of 18F-FLT PET for the suspicious lesions on mammograms and ultrasound, using the pathologic result of biopsy as gold standard, and to determine whether 18F-FLT PET can increase the specificity in breast lesion diagnosis and thus reduce the unnecessary biopsy.
- To evaluate whether 18F-FLT PET is a cost-effective imaging modality for breast cancer diagnosis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Use of 18F-FLT Positron Emission Tomography to Evaluate the Suspicious Findings on Mammography and Breast Ultrasound: A Pilot Study|
|Study Start Date :||August 2010|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2013|
18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound.
0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
Other Name: FLT
- To investigate the diagnostic accuracy of 18F-FLT PET for the suspicious lesions on mammograms and ultrasound, using the pathologic result of biopsy as gold standard. [ Time Frame: The biopsy procedures will be scheduled as soon as possible and should be finished within 2 months after 18F-FLT PET. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01713049
|Department of Medical Imaging NTUH||Recruiting|
|Taipei, Taiwan, 100|
|Contact: Jane Wang, MD, PhD +886-2-23123456 ext 65565 email@example.com|
|Principal Investigator:||Jane Wang, PhD||National Taiwan University Hospital|